Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Propecia

This article was originally published in The Tan Sheet

Executive Summary

Rx hair regrowth treatment (finasteride) is "not an effective treatment for women with hair loss," the company says May 4, reporting new study results. The product was approved by FDA for Rx use in men Dec. 19 ("The Tan Sheet" Jan. 5, pp. 14-16). Presented at a conference in Brussels, the study showed that among 65 post-menopausal women treated with Propecia for one year, there was an 8.4% decrease in hair count in the scalp areas examined; among 69 women given placebo, there was a 6.5% decrease. The new results may bolster Rogaine sales. Pharmacia & Upjohn sells Rogaine for Women (minoxidil 2% solution) and is conducting a study on the use of topical 5% minoxidil solution in women, expected to be completed in 1999. Minoxidil 5% is the active ingredient in P&U's Rogaine Extra Strength For Men, launched in January ("The Tan Sheet" Jan. 5, p. 13)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel